^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Excerpt:
...Histologically or cytologically confirmed, locally advanced and/or metastatic IIIB, IIIC or IV non-squamous NSCLC or recurrent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del and/or 21 L858R gene mutation 4....
Trial ID:
Source:
Title:
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
Excerpt:
...Signed and dated informed consent 18-75years，ECOG PS：0-2，Life expectancy of more than 3 months，with measurable lesion ( RECIST1.1) Histologically or cytologically confirmed, locally advanced and/or metastatic IIIB, IIIC or IV non-squamous NSCLC or recurrent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del or 21 L858R gene mutation and concomitant others....
Trial ID:
Less C2 evidence
Source:
Title:
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
Published date:
08/05/2023
Excerpt:
Eligible patients had histologically or cytologically confirmed stage IIIB/IV or postoperative recurrent non-squamous NSCLC with EGFR-sensitizing mutations (exon 19 deletion or Leu858Arg mutation)….anlotinib combined with icotinib is effective and tolerable in the first-line treatment of EGFR mutated advanced NSCLC with or without concurrent mutations.
DOI:
https://doi.org/10.1186/s12943-023-01823-w
Trial ID:
